Molecular Classification of Infiltrating Breast Cancer: Toward Personalized Therapy

• DOI: 10.1148/rg.345130049
• Publication Date: 2014-09-18T20:20:46Z
• Authors: Isabelle Trop; Sophie M. LeBlanc; Julie David; Lucie Lalonde; Danh Tran-Thanh; Maude Labelle; Mona M. El Khoury
• Keywords: Targeted Therapy

Breast cancer is a heterogeneous disease, which comprises several molecular and genetic subtypes, each with characteristic clinicobiologic behavior imaging patterns. Traditional classification of breast based on the histopathologic features but offers limited prognostic value. Novel characterization cellular markers has allowed new that value, predictive categories disease aggressiveness. These signatures also open door to personalized therapeutic options, receptor-targeted therapies. For example, invasive subtypes such as luminal A B show better prognosis response hormone receptor–targeted therapies compared triple-negative subtypes; other hand, tumors respond than chemotherapy. Tumors display amplification oncogene ERBB2 (also known HER2/neu oncogene) drugs directed against this oncogene, trastuzumab. The aspects correlate subgroups, well pathologic nuclear grade. Smooth tumor margins at mammography may be suggestive cancer, human epidermal growth factor receptor 2 (HER2)–positive characteristically spiculated mass calcifications. Low-grade ductal carcinoma in situ (DCIS) detected mammography, although magnetic resonance (MR) allow high-grade DCIS. MR diffusion sequences higher values for apparent coefficient HER2-positive tumors. useful tool prediction after chemotherapy, especially subtypes. ©RSNA, 2014